Early asset assessment informing BD&L due diligence

Early asset assessment informing BD&L due diligence

Goal

The client had a BD&L opportunity for an asset being explored in ongoing phase 1/2a clinical trials for two rare diseases indications related to inherited blood disorders. In order to inform the BD&L decision, the disease background and current treatment options, future treatment and potential market impact, the epidemiology/ price potential and Market Access implications needed to be understood for the EU5 and the US.

Approach

Current SoC

Current treatment options and the unmet need given Standard of Care (SoC)

Future treatments

Future treatment options, potential market impact and room for “innovation”

Potential for BD&L

Epidemiology/ price potential and implications for Market Access

  • Provided input for comprehensive BD&L due diligence assessment, focusing on Market Access/ pricing
  • Aligned cross-functional team on the epidemiology/ value scenarios to be looked into for each indication
  • Gained insights on the pricing potential leveraging our Analogue Value Assessment (AVA) approach
  • Surfaced Market Access implications at the country level (where relevant)
Our analogue value assessment (AVA) methodology

Contact our experts

Anastasia Felker

Anastasia Felker

Manager

mail_icon linkedin_icon
Clifford Hall

Clifford Hall

Subject Matter Expert

mail_icon

Learn more about our focus topic

Early Asset Strategy

We use cookies to ensure we give you the best experience on our website. Detailed information on the use of cookies, and how you can disable them, is provided in our Privacy Policy. By using this site or clicking on "OK", you consent to the use of cookies.

OK